Bessemer Venture Partners predicted that 2026 will be a breakout year for healthcare AI, driven by increased adoption of clinical AI, a new class of AI-first value-based care companies, and the emerging digital health category of data infrastructure tools. The post How Bessemer Sees 2026 Shaping Up as Healthcare AI’s Breakout Year appeared first on…
That is the title of a paper recently accepted for publication by Value in Health with co-authors Shanshan Wang, Khounish Sharma, Kathryn Spurrier, Robert J. Nordyke. The abstract is below. Objectives To identify the types of disease most likely to be impacted by the Institute for Clinical and Economic Review’s (ICER) shared savings assumptions. Methods…
From AI to value-based care, three VCs shared their controversial takes on healthcare during a recent panel discussion at the MedCity INVEST conference. The post 3 Health Investors Share Their Most Controversial Industry Takes appeared first on MedCity News.
Real change will come from disrupting the status quo. Advances in AI and a focus on prevention offer a way forward, promising not just financial rewards, but a healthier population, less strain on healthcare, and a future where “healthcare” truly means care. The post Disrupting the U.S. “Sickcare” System appeared first on MedCity News.
Medicare margins are expected to stay above 3 percent in 2026
Northwestern University economist Chuck Manski studies decision-making amid uncertainty. That prepared him better than many other cancer patients to decide whether to stay on an immunotherapy treatment that was making him very ill. For six months in 2022, Manski received monthly infusions of nivolumab to fight advanced melanoma. The drug ruined his thyroid gland, he…
When home dialysis is done right, care partners quickly discover they are becoming an integral part of the process as engaged, informed participants rather than uninformed outside observers. By knowing more, care partners can worry a lot less. The post When Dialysis Comes Home, Patients and Care Partners Flourish appeared first on MedCity News.
Rick Pazdur, formerly the FDA’s top oncology official, said the FDA is at a critical juncture that could determine the direction of the world’s top regulator of medicines. Pazdur spoke during a STAT panel discussion during the annual meeting of the American Society of Clinical Oncology. The post Former FDA Officials: There’s Opportunity to Rebuild…
With positive Phase 1 results for the metabolic disorder drug MZE782, Maze Therapeutics plans to advance the small molecule to Phase 2 tests in phenylketonuria and chronic kidney disease. Following the data readout, Maze raised $150 million in a private placement. The post Maze Therapeutics Drug Shows Potential to Top Asset Acquired by Otsuka for…
That is the title of a new paper published in the American Journal of Managed Care (AJMC) with co-authors Jacob Fajnor, Shurui Zhang, and Donald Nichols. The abstract is below. Objectives: To (1) develop a metric that quantitatively measures the risk that utilization management (UM) policies pose to patients and (2) measure the relationship between…